Inhibikase Therapeutics annual total assets
2020
2021
2022
2023
2024
2025
Inhibikase Therapeutics Total Assets Growth & History (IKT)
Inhibikase Therapeutics's total assets was $181.2M for fiscal 2025.
View full Inhibikase Therapeutics company overviewInhibikase Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $181.2M | $82.6M | +83.78% |
| 2024 | 2024-12-31 | $98.6M | $84.1M | +579.69% |
| 2023 | 2023-12-31 | $14.5M | −$10.4M | −41.83% |
| 2022 | 2022-12-31 | $24.9M | −$17.5M | −41.28% |
| 2021 | 2021-12-31 | $42.5M | $27.7M | +187.30% |
| 2020 | 2020-12-31 | $14.8M | — | — |
Inhibikase Therapeutics quarterly total assets
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $163.6M | $74.7M | +84.11% |
| Q1 2026 | 2026-03-31 | $173.3M | $79.1M | +83.85% |
| Q4 2025 | 2025-12-31 | $181.2M | $82.6M | +83.78% |
| Q3 2025 | 2025-09-30 | $79.6M | $75.2M | +1718.52% |
| Q2 2025 | 2025-06-30 | $88.9M | $80.0M | +906.63% |
| Q1 2025 | 2025-03-31 | $94.3M | $83.2M | +751.83% |
| Q4 2024 | 2024-12-31 | $98.6M | $84.1M | +579.69% |
| Q3 2024 | 2024-09-30 | $4.4M | −$13.5M | −75.52% |
| Q2 2024 | 2024-06-30 | $8.8M | −$13.5M | −60.50% |
| Q1 2024 | 2024-03-31 | $11.1M | −$17.1M | −60.70% |
| Q4 2023 | 2023-12-31 | $14.5M | −$10.4M | −41.83% |
| Q3 2023 | 2023-09-30 | $17.9M | −$10.7M | −37.44% |
| Q2 2023 | 2023-06-30 | $22.3M | −$11.6M | −34.26% |
| Q1 2023 | 2023-03-31 | $28.2M | −$10.2M | −26.64% |
| Q4 2022 | 2022-12-31 | $24.9M | −$17.5M | −41.28% |
| Q3 2022 | 2022-09-30 | $28.6M | −$17.3M | −37.69% |
| Q2 2022 | 2022-06-30 | $34.0M | −$15.2M | −30.93% |
| Q1 2022 | 2022-03-31 | $38.4M | $26.5M | +223.31% |
| Q4 2021 | 2021-12-31 | $42.5M | $27.7M | +187.30% |
| Q3 2021 | 2021-09-30 | $45.9M | — | — |
| Q2 2021 | 2021-06-30 | $49.2M | — | — |
| Q1 2021 | 2021-03-31 | $11.9M | — | — |
| Q4 2020 | 2020-12-31 | $14.8M | — | — |
Inhibikase Therapeutics total assets trends
Over the last five fiscal years, Inhibikase Therapeutics's total assets increased from $14.8M to $181.2M, a change of $166.4M. The latest reported quarter, Q2 2026, shows $163.6M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inhibikase Therapeutics source filings ↗